Dr Reddy's Introduces Non-Invasive Migraine Management Wearable Device

Dr Reddy's Laboratories, a pharmaceutical company, declared the launch of the medication-free painless migraine management wearable gadget Nerivio in Germany through its step-down auxiliary Betapharm. The launch also marks the organization's entrance into digital therapeutics in Europe. Nerivio is sanctioned by the US Food and Drug Administration (US FDA) and is CE-mark confirmed in Europe.

Nerivio was introduced in 2023 by Dr Reddy at the DGN Kongress, coordinated by the German Relationship of Neurology in Berlin and the seventeenth European Headache Congress held in Barcelona, Spain. Dr Reddy's will present and introduce Nerivio during the Neurological Association of South Africa yearly congress on April 17, 2024, in the presence of Dr Stewart Tepper, Professor of Nervous System Science, Geisel Institute of Medication—Dartmouth, and VP, New England Foundation for Neurology and Headache. 

In the previous year, Dr Reddy's entered into a selective concurrence with Theranica, an endorsed digital therapeutics organization creating advanced neuromodulation gadgets for migraine and other painful conditions, for the promotion and dissemination of Nerivio in different business sectors.

The pharmaceutical firm introduced Nerivio in India in 2023. In India, Nerivio is upheld by Dr. Reddy's exceptional patient help program called ‘M-Free.’ The program is an emotionally supportive network that upgrades and smoothes out the patients' journey. M-Free incorporates administrations, for example, onboarding and directing of patients, device demonstrations, doorstep conveyance, adaptable installment choices and customer client care to assist patients with taking advantage of the gadget. With the way of life change as a vital proposal for better-managing migraine, the M-Free mindfulness program offers a set-up of worth-added administrations, for example, nutritionist counsel, yoga and reflection meetings with ensured experts for all-encompassing medication-free migraine management.